Acurx Pharmaceuticals, Inc. (ACXP)
1.135
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
1.135
0.00 (0.00%)
After-Hours: 20:00
Acurx Pharmaceuticals Enterprise Value : -5.341M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -5.341M |
| October 22, 2026 | -5.317M |
| October 21, 2026 | -5.271M |
| October 20, 2026 | -5.317M |
| October 19, 2026 | -5.317M |
| October 16, 2026 | -5.505M |
| October 15, 2026 | -5.177M |
| October 14, 2026 | -5.271M |
| October 13, 2026 | -5.036M |
| October 12, 2026 | -4.662M |
| October 09, 2026 | -4.709M |
| October 08, 2026 | -4.802M |
| October 07, 2026 | -4.568M |
| October 06, 2026 | -4.521M |
| October 05, 2026 | -4.521M |
| October 02, 2026 | -4.709M |
| October 01, 2026 | -4.755M |
| September 30, 2026 | -4.755M |
| September 29, 2026 | -4.545M |
| September 28, 2026 | -4.381M |
| September 25, 2026 | -4.287M |
| September 24, 2026 | -4.287M |
| September 23, 2026 | -4.240M |
| September 22, 2026 | -4.287M |
| September 21, 2026 | -4.428M |
| Date | Value |
|---|---|
| September 18, 2026 | -4.147M |
| September 17, 2026 | -4.147M |
| September 16, 2026 | -4.193M |
| September 15, 2026 | -4.310M |
| September 14, 2026 | -4.147M |
| September 11, 2026 | -4.100M |
| September 10, 2026 | -4.100M |
| September 09, 2026 | -4.053M |
| September 08, 2026 | -3.959M |
| September 04, 2026 | -4.006M |
| September 03, 2026 | -4.100M |
| September 02, 2026 | -3.959M |
| September 01, 2026 | -4.100M |
| August 31, 2026 | -3.866M |
| August 28, 2026 | -3.912M |
| August 27, 2026 | -3.819M |
| August 26, 2026 | -3.959M |
| August 25, 2026 | -4.053M |
| August 24, 2026 | -4.100M |
| August 21, 2026 | -3.772M |
| August 20, 2026 | -3.866M |
| August 19, 2026 | -3.912M |
| August 18, 2026 | -3.912M |
| August 17, 2026 | -2.929M |
| August 14, 2026 | -4.123M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.254M |
| Total Expenses (Quarterly) | 2.254M |
| EPS Diluted (Quarterly) | -0.5292 |
| Earnings Yield | -268.3% |
| Normalized Earnings Yield | -268.32 |